Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
The Coverage Battle Continues for Veterans With Transthyretin Amyloidosis
The Veterans Health Administration exists to integrate health care services for those who served in the U.S. Armed Forces. Yet for many veterans, getting access to treatment for transthyretin amyloidosis, a rare disease caused by a buildup of abnormal proteins, is difficult.
As a health system, the VA covers a large proportion of transthyretin amyloidosis patients because the condition usually presents in older adults, particularly older men. It is not a secret that medications used in the treatment of transthyretin amyloidosis are very expensive, and the VA does an excellent job in requiring patients to be responsible for only small monthly co-pay.
The VA has the opportunity to lead the way in providing patient-centered care for the historically untreatable disease. It should, however, work for best patients’ care rather than restricting physicians and limiting patients’ access.
Veterans with transthyretin amyloidosis are fighters, having first served their country and then forced to battle a progressive and rare disease. They shouldn’t have to also fight for access to the health care they rightfully earned.
myBinderRelated Content
-
Hereditary Transthyretin AmyloidosisHereditary transthyretin (ATTR) amyloido...
-
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyBackground: Transthyretin (TTR) amyloid...
-
Transthyretin Amyloidosis: Information for Patients and FamilyWhat is transthyretin amyloidosis? Tran...
-
Dr. Wechalekar’s Interview on Burden of Diseasehttps://www.youtube.com/watch?v=Q-aaIPMa...
-
Gene Editing Offers Hope for Progressive Cardiomyopathy Due to AmyloidosisInvestigators have found that intravenou...
-
Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospect...Background: Heart failure caused by wil...
-
Transthyretin Cardiac Amyloidosis in Black AmericansTransthyretin-related cardiac amyloidosi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
